Metastasis From Malignant Tumor of Liver clinical trials at UCSF
1 research study open to eligible people
Metastasis from a malignant tumor of the liver means cancer has moved from the liver to other areas. UCSF is testing NBTXR3 combined with radiotherapy and anti-PD-1 therapy in advanced cancer patients. This research could improve how we treat liver cancer.
Showing trials for
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Last updated: